Health Care Weekly: FDA Leaders Open to Regulatory Flexibility on Psychedelics; House E&C Panel May Back Medicare Coverage for Respiratory Illness Care at Pharmacies; Patients, Plans Push for No Surprises Act Dispute Resolution Changes; CMS Can Better Screen for DME Fraud in Medicare Advantage, HHS-OIG Says

The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re following this week include: • FDA officials say they’re open to regulatory flexibility on psychedelic drugs. • House E&C Committee appears supportive of extending Medicare reimbursements to pharmacists who […]